Down 8%, is this a rare opportunity to buy this overlooked FTSE powerhouse stock?

Despite strong H1 results, this FTSE 100 medical technology heavyweight’s shares have fallen, and now look even more undervalued to me.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Person holding magnifying glass over important document, reading the small print

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100’s Smith & Nephew (LSE: SN) has fallen 8% from its 1 August 12-month high of £12.46. That day saw the release of better-than-expected H1 2024 results.

However, the day after that the market began to slide following worse-than-expected US jobs data, taking Smith & Nephew’s share price with it. 

This has created a rare opportunity to buy the stock on a dip, I think.

Should you invest £1,000 in Scottish Mortgage right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Scottish Mortgage made the list?

See the 6 stocks

How undervalued are the shares now?

Even before the FTSE 100 sell-off, the medical technology stock looked a bargain to me.

On the key price-to-book ratio (P/B) stock valuation measure, it now trades at 2.5 against a peer group average of 3.6.

On the price-to-sales ratio (P/S), it is currently at 2.3 compared to the 3.3 average of its competitors.

To work out how much value is in the stock, I ran a discounted cash flow analysis using other analysts’ figures and my own.

This shows the shares to be around 35% undervalued at their present price of £11.46. So a fair value for the stock would be £17.63.

Created with Highcharts 11.4.3Smith & Nephew Plc PriceZoom1M3M6MYTD1Y5Y10YALL14 Aug 201914 Aug 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.co.uk

It may go lower or higher than that, but it underlines to me how cheap the stock looks.

How strong is the business?

Its H1 results showed trading profit jumping 12.8% from H1 2023 — to $471m, ahead of analysts’ forecasts of $462m. There was also a rise in trading profit margin to 16.7% from 15.3%. And adjusted earnings per share (EPS) increased 7.7% to 37.6 cents (29.5p).

These numbers in part reflected major advances in some of the firm’s key products in that period.

For example, it fully commercially launched the AETOS shoulder system – one of the fastest-growing markets in orthopaedics. It also gained US regulatory approval for its new CATALYSTEM hip technology.

A risk for the firm is a fundamental failure in any of its core products, which could prove costly to fix. Additionally, any litigation arising from the ill effects of any of its products could damage its reputation.

However, consensus analysts’ forecasts are that its earnings will grow 22.8% a year to end-2026. EPS is expected to rise by 27.1% a year to that point.

So will I buy the shares?

A key consideration in stock selection is knowing where one is in the investment cycle, in my experience.

The further a person is from when they want to retire, the longer the markets have to recover from any shocks. The same is true for individual stocks as well.

This means two things to me in practical terms. First, the younger a person is, the more risk they can afford to take in the stocks they choose. And second, they can focus more on a balance of growth shares and those geared to paying regular dividend income.

I am well over 50 now and am focused almost entirely on these high-yielding stocks. I am using the dividends paid me to increasingly reduce my working commitments and will continue to do so.

Smith & Nephew currently yields 2.6%. This is better than nothing but nowhere near the 9% average of my high-yielding shares.

Consequently, I will not be buying the stock. If I were 10 years younger I would do so because of its significant undervaluation and the firm’s strong growth prospects.

5 stocks for trying to build wealth after 50

The cost of living crisis shows no signs of slowing… the conflict in the Middle East and Ukraine shows no sign of resolution, while the global economy could be teetering on the brink of recession.

Whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times. Yet despite the stock market’s recent gains, we think many shares still trade at a discount to their true value.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. We believe these stocks could be a great fit for any well-diversified portfolio with the goal of building wealth in your 50’s.

Claim your free copy now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Simon Watkins has no position in any of the shares mentioned. The Motley Fool UK has recommended Smith & Nephew Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Dividend investors! Here’s what Warren Buffett says builds wealth in the stock market

Reinvesting dividends at yields of 8% or higher looks like a good way of building wealth. But Warren Buffett has…

Read more »

Calendar showing the date of 5th April on desk in a house
Investing Articles

Here’s my Stocks and Shares ISA plan for 2025-26

A Stocks and Shares ISA helps investors avoid taxes on dividends and capital gains. And Stephen Wright has a plan…

Read more »

Dividend Shares

Of the 20 highest-yielding FTSE 100 stocks, this is my top pick

This FTSE 100 stock currently offers a yield of 6.4%. But Edward Sheldon believes it’s capable of providing share price…

Read more »

Investing Articles

Could Tesla’s share price jump over the next 12 months? These analysts think so!

Tesla's share price has fallen by almost a third since 1 January. But optimism is high that Elon Musk's company…

Read more »

Investing Articles

I asked ChatGPT where the FTSE 100 will be in 6 months: here’s what it said…

Let’s be realistic, ChatGPT can’t predict the future. But it did do a good job of compiling data from brokerages…

Read more »

Investing Articles

Could the Rolls-Royce share price hit £10?

The Rolls-Royce share price has taken most analysts by surprise with almost everything going right for the British engineering giant.

Read more »

Investing Articles

4 REITs Fools own for passive income

REITs often have higher-than-average dividend yields compared to other stocks, making them a solid choice to consider for passive income…

Read more »

artificial intelligence investing algorithms
Investing Articles

Up 272% in just a year, is Palantir stock just getting started?

This writer recognises that Palantir has grown its business very well -- but does the stock price offer him an…

Read more »